Summary of Key Points from Conference Call Records Industry Overview - **Industry Focus**: Innovative pharmaceuticals, particularly in the context of China's biopharmaceutical sector and its international expansion - **Market Growth**: The total value of BD (Business Development) transactions for innovative drugs is projected to reach $137.7 billion by 2025, a 1.6 times increase year-on-year, significantly surpassing the electric vehicle sector's $74 billion in the same timeframe [1][2][3] Core Insights and Arguments - **International Expansion**: The innovative drug sector is experiencing explosive growth in international markets, with Q1 2026 BD transactions already reaching $60 billion, accounting for 46% of the total for 2025 [1][2] - **Policy Support**: Biopharmaceuticals have been designated as a new pillar industry by the Chinese government, shifting focus from public welfare to GDP contribution, indicating a supportive policy environment for growth [2][3] - **Performance Expectations**: Companies like Heng Rui Medicine are expected to see over 30% growth in innovative drug revenue by 2026, with significant contributions from key products [1][3] - **Clinical Developments**: Major clinical data releases are anticipated from key conferences such as AACR and ASCO, which could catalyze market movements [1][5] Notable Companies and Their Prospects - **Heng Rui Medicine**: Expected to achieve over 30% growth in innovative drug revenue, with a strong pipeline of 53 products anticipated for approval between 2022 and 2028 [15] - **Kangfang Biopharma**: Key product AK112 is set to release critical clinical data in 2026, which could significantly impact its market position [11][13] - **Baiyi Shenzhou**: Projected profits of $700-800 million in 2026, indicating a rapid profit climb [1][8] - **Xinda Biopharma**: Anticipated to benefit from new product approvals and commercial launches, with a focus on expanding its product pipeline [6][8] Investment Opportunities - **Recommended Stocks**: Key investment targets include Kangfang Biopharma, Xinda Biopharma, Baiyi Shenzhou, and Kelong Biotechnology in the H-share market, and Xintai, Haishike, and Heng Rui Medicine in the A-share market [4][8] - **Undervalued Stocks**: Companies like Hot Scene Biopharma and Yifang Biopharma, which have seen significant price declines, are suggested for bottom-fishing opportunities [4][8] Emerging Trends - **Small RNA Technology**: The small RNA sector is entering a critical phase with breakthroughs in liver-targeted delivery technologies, and several companies are expected to announce significant clinical data in 2026 [18][22] - **Clinical Data Impact**: Recent clinical data from companies like Serapta and Wave Life Sciences highlight the potential and challenges within the small RNA space, influencing market sentiment and investment strategies [20][21] Conclusion - The innovative pharmaceutical sector in China is poised for significant growth driven by international expansion, supportive policies, and strong company performances. Key clinical events and emerging technologies present substantial investment opportunities, particularly in small RNA and innovative drug development.

Group 1 - The Hong Kong pharmaceutical sector is experiencing a rebound, with the Hong Kong Stock Connect Innovation Drug ETF (159570) rising nearly 2% and achieving a trading volume exceeding 2.05 billion yuan, leading its peers with a total scale of over 22.8 billion yuan [1] - The 2026 European Association of Urology (EAU) annual meeting held in London showcased innovative applications of HER2-targeted antibody-drug conjugates (ADCs) in treating urothelial carcinoma, with multiple cutting-edge research results from China presented [3] - Rongchang Biopharmaceutical recently reported a revenue of 3.251 billion yuan, a year-on-year increase of 89.36%, and a net profit of 709 million yuan, marking a turnaround from losses, primarily driven by increased sales of its injectable drugs [3] Group 2 - The Hong Kong Stock Connect Innovation Drug ETF (159570) saw most of its constituent stocks perform positively, with Rongchang Biopharmaceutical up over 6%, Kangzhi Pharmaceutical up over 5%, and China Biopharmaceutical up over 3% [3] - Recent approvals for new drugs and indications in China include: 1) Hengrui Medicine's oral new drug for a new indication; 2) Roche's CD79B ADC new indication approved in China; 3) Kangzhi Pharmaceutical's new drug for renal anemia approved; 4) Junshi Biosciences' first domestic PD-1 subcutaneous formulation submitted for approval [6] - The innovative drug sector in China is transitioning from "fast following" to "innovation leading," with significant advancements in new technology platforms such as molecular glue, small nucleic acids, and in vivo CART, which are expected to enhance drug development efficiency and cost-effectiveness [7][8][9] Group 3 - The recent policy shift designating the biopharmaceutical industry as an emerging pillar industry is expected to release a series of policy dividends, indicating a positive outlook for the sector [11] - The Hong Kong Stock Connect Innovation Drug ETF (159570) is fully invested in innovative drugs, with the top ten constituent stocks accounting for 73.54% of its weight, highlighting its focus on the innovation drug sector [12]

Investment Rating - The report rates the industry as "Overweight" [4] Core Insights - The report highlights significant advancements and investment opportunities in the global innovative drug sector, particularly in weight loss, PD-1/VEGF dual antibodies, and PROTAC/molecular glue technologies [2][3] Summary by Sections Weight Loss - Novo Nordisk's REDEFINE 4 study showed that CagriSema resulted in a weight loss of 23.0% over 84 weeks compared to 25.5% for Tirzepatide, failing to meet the non-inferiority benchmark set by the company [7][8] - Following the disappointing results, Novo Nordisk is expected to accelerate the development of four next-generation weight loss assets, including Cagrilintide, Zenagamide, UBT251, and GLP-1/GIP/Amylin [12][17] PD-1/VEGF Dual Antibodies - The PD-1/VEGF dual antibody market is projected to exceed $100 billion, driven by longer duration of treatment and survival benefits compared to PD-1 monotherapy [19] - The HARMONi-3 study has completed enrollment of 600 patients, with plans for an interim analysis in Q2 2026, which may support accelerated approval discussions with the FDA [22][23] PROTAC/Molecular Glue - The report notes positive developments in PROTAC and molecular glue technologies, particularly in autoimmune diseases and oncology [27] - Monte Rosa's NEK7 molecular glue MRT-8102 has shown promising early results, potentially offering a competitive edge in reducing systemic inflammation [28][31] Small Nucleic Acids - Early studies of ARO-INHBE and ARO-ALK7 suggest potential for competitive weight loss effects and safety profiles when combined with low-dose GLP-1 [27] - The report emphasizes the shift from single-target RNAi to combination therapies for lipid reduction, marking a significant evolution in treatment strategies [27] In Vivo CAR-T - Eli Lilly's acquisition of Orna for $2.4 billion underscores the growing strategic interest in in vivo CAR-T therapies, which aim to simplify production while ensuring controlled expansion and safety [27]

Core Viewpoint - The report emphasizes the importance of capturing structural opportunities in the pharmaceutical sector, particularly focusing on medical/healthcare AI and stocks with positive fundamental changes [1] Market Performance - The Shanghai and Shenzhen 300 index rose by 0.36%, while the pharmaceutical and biological sector declined by 0.81%, ranking 21st among 31 primary sub-industries this week [1] - The medical services sector increased by 0.22%, while the chemical pharmaceuticals, biological products, medical devices, traditional Chinese medicine, and pharmaceutical commerce sectors fell by 0.54%, 0.89%, 1.07%, 1.75%, and 2.68% respectively [1] Investment Opportunities - The pharmaceutical market is showing clear segmentation, with AI healthcare, small nucleic acid-related stocks that have recently corrected, and stocks with marginal fundamental changes and lighter institutional holdings performing well [1] - The pharmaceutical sector, combining technology and consumer attributes, is expected to continue exhibiting structural trends amid market rotations [1] - The innovative drug sector has experienced a significant rise followed by a correction over the past year, with valuations generally considered reasonable compared to early 2025 levels [1] Recommended Focus Areas - It is advised to pay attention to specific sub-sectors such as small nucleic acids, in vivo CAR, ADC, second-generation IO, and PROTAC, as well as companies with marginal fundamental changes that are likely to realize sustained performance [1] - The medical/healthcare AI+ sector is highlighted as a recently popular direction, suggesting a focus on leading companies in this field, as well as those with non-pharmaceutical/healthcare AI+ core businesses that are actively embracing related technologies and expected to realize valuation flexibility in the short to medium term [1] - In the consumer aspect, with 2025 performance forecasts largely reflected in current stock prices, attention is recommended on traditional Chinese medicine and medical beauty sectors that are actively expanding their product offerings, as well as the medical services sector that has undergone long-term adjustments [1]

Core Viewpoint - The company has focused on the small nucleic acid sector for several years, driven by the clinical application and market potential of this field [1] Group 1: Clinical Value and Competitive Advantage - The company emphasizes the potential clinical value and differentiated competitiveness of its products, assessing efficacy, safety, and dosing frequency compared to existing and in-development drugs [1] - Market space and unmet clinical needs are also considered during pipeline project evaluations [1] Group 2: Internal Capabilities and Experience - The company has over 20 years of experience in peptide drug development, particularly in long-acting delivery technologies, which can be leveraged in small nucleic acid drug development [1] - A successful development of Aikening has established a comprehensive R&D system from early project initiation to non-clinical research, ensuring efficient execution and understanding of the entire new drug development process [1] Group 3: Future Expectations - The company looks forward to sharing new progress and results in the small nucleic acid field with investors in the near future [1]

Investment Rating - The industry investment rating is maintained at "Overweight" [7] Core Insights - The report highlights the continuous upgrading of policies in the Heilongjiang biomanufacturing industry, focusing on innovative traditional Chinese medicine and innovative medical devices [4] - The report emphasizes the significant revisions to the Drug Administration Law, which provides institutional support for pharmaceutical innovation and high-quality development [4] - The report identifies three major transformations in China's innovative drug business development (BD) in 2026: technology output combined with product authorization, platform cooperation, and global parallel innovation [8] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -7.06% compared to the CSI 300 index, with an absolute return of 11.53% [3] Investment Highlights - The report notes that BD transactions in the pharmaceutical sector are focused on unmet clinical needs, technological differentiation, and global value [6] - Key areas of focus include oncology therapies such as dual antibodies, ADCs, and TCE combinations, with significant financial agreements highlighted, such as a $650 million upfront payment for a PD-1/VEGF dual antibody [6] - The metabolic disease sector is centered on long-acting GLP-1 and small nucleic acid precision therapies, with notable collaborations resulting in substantial upfront payments and potential total amounts [6] Company-Specific Developments - Companies like Andover Pharmaceuticals and Frontier Biotech have secured significant collaborations with major pharmaceutical firms, indicating a trend towards platform-based cooperation and technology output [7] - Specific collaborations include a $1.05 billion deal for a CTLA-4 inhibitor and a $400 million agreement for small nucleic acid drugs, showcasing the growing interest in innovative therapies [7] - The report suggests monitoring companies such as Rebio Biotech and WuXi AppTec for their advancements in small nucleic acids and platform capabilities [8]

Core Viewpoint - Frontier Biotech has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small RNA (siRNA) pipeline products, which includes a candidate drug that has reached the IND stage and another that is still in preclinical phase [1][2] Financial Aspects - Frontier Biotech will receive an upfront payment of $40 million and a milestone payment of $13 million, with potential additional milestone payments totaling up to $950 million for the two projects [1] - The company's market capitalization is approximately 9.3 billion yuan, with a stock price increase of 9.29% on the day of the announcement, closing at 24.7 yuan per share [2] - Financial data indicates that Frontier Biotech's revenue is projected to grow from 40 million yuan in 2020 to 120 million yuan in 2024, but the company has accumulated losses exceeding 1.7 billion yuan [5][7] Product Development - The collaboration with GSK allows Frontier Biotech to manage early development work, including Phase I clinical trials in China, while GSK will handle global clinical development and commercialization [1][2] - The specific project codes for the licensed products have not been disclosed, but one candidate drug for IgA nephropathy has reached the IND stage [2][3] Strategic Positioning - The partnership with GSK is seen as a means to improve cash flow for Frontier Biotech, which has faced cash pressure due to high R&D expenses and limited commercial success from its existing products [5][7] - The company has shifted its focus to small RNA drugs after previously developing HIV treatments, indicating a strategic pivot in response to market conditions [7][10] Industry Context - The small RNA drug sector is gaining attention, with potential applications targeting pathogenic genes, although technical challenges remain, particularly in non-liver delivery systems [11] - The market for small RNA drugs is expected to grow, with several products in clinical stages for various indications, including hepatitis B and hypertension [11]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for Heng Rui Pharmaceutical (600276) and "Increase" for WuXi Biologics (603259) [46] Core Insights - The recent national drug procurement has been stable, with active participation from companies and continued benefits for patients [8][9] - The issuance of the "National Basic Drug Directory Management Measures" aims to enhance the management of essential medicines [10][11] - Heng Rui Pharmaceutical reported positive top-line results for its GLP-1/GIP dual receptor agonist, indicating significant weight loss in clinical trials [12] - The approval of Mu Feng Da® for the treatment of adult type 2 diabetes marks a significant development in the market [12] Industry News - The national drug procurement involved 316 commonly used drugs across 26 therapeutic areas, with a high participation rate from over 5,100 medical institutions and 1,091 companies [8][9] - The procurement process has been standardized, allowing companies to bid online once for nationwide sales, significantly reducing costs [9] - The management measures for the national basic drug directory have been revised to include legal policy bases and optimize the directory structure [10][11] Company Announcements - Innovent Biologics has entered a global strategic partnership with Eli Lilly to advance new drug development in oncology and immunology [26] - Kelun Pharmaceutical's TROP2 ADC has received approval for a fourth indication from the NMPA [27] - Heng Rui Pharmaceutical's drug has been included in the list of breakthrough therapy products, and its application for marketing approval has been accepted for priority review [28] - WuXi Biologics has forecasted a positive earnings outlook, expecting a revenue increase of approximately 16.7% [30] Market Review - The Shanghai Composite Index rose by 1.43%, while the Shenzhen Component Index increased by 2.37%, with the SW Pharmaceutical and Biotech Index up by 0.23% [36] - The industry’s price-to-earnings ratio (TTM) stands at 51.17, with a valuation premium of 259% compared to the CSI 300 [40] Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring performance recovery indicators [46]

Summary of Industry Reports Industry: Pharmaceutical and Biotechnology Key Points from Document 1 1. **Raw Material Supply Changes**: The supply of raw materials is accelerating, with a focus on subsequent volume and price changes [1] 2. **Global GLP-1 Landscape**: The global GLP-1 landscape is continuously evolving, and Chinese companies are still pursuing international expansion [1] 3. **Small Nucleic Acid Sector**: Leading companies are gradually entering the small nucleic acid field, with market progress expected to drive the development of supporting industrial chains [1] 4. **Retail Pharmaceutical Market Outlook**: The retail pharmaceutical market is expected to improve by Q4 2025, with an enhanced positioning of chain pharmacies [1] 5. **Value of Oral Immunomodulatory Drugs**: Emphasis on the market value of oral immunomodulatory drugs [1] 6. **Investment Recommendations**: Recommended companies include Chuaning Biological, with attention to Lianbang Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, as well as synthetic biology companies [1] 7. **CXO Order Trends**: Positive trends in CXO orders and rising prices for safety evaluation orders, with recommendations for Yinos and Zhaoyan New Drug, and recommendations for Weiya Biological and Puris [1] Key Points from Document 2 1. **Small Nucleic Acids Breakthrough**: Continuous breakthroughs in small nucleic acids, with ongoing progress in external authorizations by Chinese companies, recommending Yuekang Pharmaceutical and Sunshine Novo [2] 2. **Self-Immunity Field**: Focus on breakthroughs in oral directions and difficult-to-treat areas like UC/IBD, recommending Yahong Pharmaceutical and Yifang Biological [2] 3. **GLP-1 Weight Loss Authorizations**: Recommendations for Zhongsheng Pharmaceutical in the GLP-1 weight loss field, with attention to Lianbang Pharmaceutical and Shiyao Group [2] 4. **ZAP-X Radiation Therapy Equipment**: Initiation of domestic clinical research for ZAP-X radiation therapy equipment, recommending Baiyang Pharmaceutical [2] 5. **Policy Support for Brain-Computer Interface Technology**: Support for the development of invasive brain-computer interfaces, recommending Meihao Medical and Botuo Biological, with accelerated approvals for non-invasive devices, focusing on Xiangyu Medical and Kefu Medical [2] 6. **High-Value Medical Device Exports**: Breakthroughs in exports of high-value medical consumables, with attention to Chunli Medical, Aikang Medical, Nanwei Medical, and Baixin An [2] 7. **AI in Healthcare**: Accelerated applications of AI in healthcare, reshaping application scenarios and bringing changes in industrial chain value, recommending Anbiping and focusing on Yuyue Medical and Meinian Health [2] 8. **Chain Pharmacy Industry**: Industry consolidation in chain pharmacies, with policy support for enhanced positioning, recommending Yifeng Pharmacy and Laobaiqing, with attention to Yixintang [2]